{"id":"https://genegraph.clinicalgenome.org/r/a7ffb156-2d84-47b9-b6a4-99abc05ddbf9v1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between NDUFAF2 and Leigh syndrome spectrum was evaluated using the ClinGen Clinical Validity Framework as of April 20, 2020. The NDUFAF2 gene encodes NADH:ubiquinone oxidoreductase (complex I) assembly factor 2. Defects of this protein lead to a complex I deficiency.\n\nThe NDUFAF2 gene was first reported in relation to autosomal recessive Leigh syndrome spectrum in 2005 (PMID: 16200211). Evidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included six unique variants identified in seven cases from five publications (PMIDs: 16200211, 18180188, 19384974, 20571988, 20818383). No segregation data were available. Loss of function is implicated as the mechanism of disease. This gene-disease association is also supported by biochemical function, expression data, and cell culture models (PMIDs: 27977873, 16200211, 25613900, 23702311). \n\nIn summary, there is definitive evidence to support this gene-disease relationship, including that more than three years have elapsed from the first proposal of the association. This classification was approved by the NICHD U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on April 20, 2020 (SOP Version 7).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/a7ffb156-2d84-47b9-b6a4-99abc05ddbf9","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7c26c06d-17dc-4783-8145-5de35c9a73f5","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7c26c06d-17dc-4783-8145-5de35c9a73f5_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2020-11-23T19:37:03.831Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/7c26c06d-17dc-4783-8145-5de35c9a73f5_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2020-11-23T19:36:34.959Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7c26c06d-17dc-4783-8145-5de35c9a73f5_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15a117ff-df0b-4343-ab32-a23a3dac37ef_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Patient is homozygous for a nonsense mutation c.9G > A which introduces an early stop codon at position 3 of NDUFAF2 (p.Trp3X),","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d9fc1191-cc5e-44b8-8e5b-636ab4f30ced","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20571988","rdfs:label":"Herzer Index","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":26,"detectionMethod":"Genomic DNA was extracted from skeletal muscle homogenate by proteinase K treatment followed by phenol / chloroform extraction. Mutation screen in candidate genes including NDUFAF2 was performed by high-resolution melting analysis. All exons of NDUFAF2 were PCR amplified by intronic primers and altered melting curves compared were directly sequenced. Sanger sequencing of the entire mitochondrial DNA failed to detect a mutation. High-resolution melting profile analysis of exonic sequences from NDUFAF2 revealed a novel homozygous nonsense mutation c.9G > A introducing an early stop codon at position 3 of NDUFAF2 (p.Trp3X,)","firstTestingMethod":"High resolution melting","phenotypeFreeText":"With respiratory infection, he was found to be apnoeic, cyanotic and comatose. On admission he was mechanically ventilated and presented with foot drop position and bilateral positive Babinski signs. Neuroimaging at the age of 27 month revealed on T 2 -weighted images lesions in the upper cervical spinal cord, the medulla oblongata, in the pontine tegmentum, in the midbrain in the substantia nigra and the periaqueductal\nregion. In the cerebral white matter patchy and not completely confluent lesions, mainly located in the frontal and parietal deep white matter, are seen. The corpus callosum,\ninternal capsule and basal ganglia and thalami are spared (Images available for review).Activities of the respiratory chain complexes were determined in isolated fibroblast mitochondria and in muscle homogenate. The complex I activity was clearly reduced with 12 % residual activity of the lowest control value in muscle and 59 % in fibroblasts. Neuropathological examination of CNS revealed softening and brown discolouration of the substantia nigra and the tegmentum of the brainstem and typical signs of Leigh disease\nwith necrosis, spongy state and capillary proliferation predominantly in the brainstem (substantia nigra, tegmentum of mesencephalon, pons and medulla oblongata), the optic nerves and chiasma. (Additional neuropath language available for review)","phenotypes":["obo:HP_0004913","obo:HP_0001263"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/15a117ff-df0b-4343-ab32-a23a3dac37ef_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20571988","allele":{"id":"https://genegraph.clinicalgenome.org/r/765b6df9-f9bb-4788-8ce4-b289dcc9d5db","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_174889.5(NDUFAF2):c.9G>A (p.Trp3Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA359935468"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b62ddd0e-387c-4b42-b2b5-56bdea337df0_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The c.1A>T mutations results in a substitution of the first methionine by leucine (Met1Leu).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/441c549a-5729-4693-aaba-c97584ae92e3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18180188","rdfs:label":"Barghuti Patient 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":20,"detectionMethod":"","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"At 20 months she was found apneic and cyanotic. On admission she was unconscious, flaccid, the pupils were semi-constricted and there was external ophthalmoplegia.On discharge she was alert and oriented, breathed spontaneously and fed by mouth; muscle tone was low but there was no overt weakness. Eye movements were normal but there was horizontal and rotatory nystagmus with dysmetria and trunk ataxia. Brain MRI at 20 mos disclosed symmetric lesions in the mamillothalamic tracts, substantia nigra/medial lemniscus, medial longitudinal fasciculus and spinothalamic tracts. The corpus medullare and the cerebellum were affected in a confluent manner. The cortex and subcortical white matter were relatively spared (Images available for Review). Complex I activity in fibroblasts was 36% of control.","phenotypes":["obo:HP_0002078","obo:HP_0002123"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b62ddd0e-387c-4b42-b2b5-56bdea337df0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18180188","allele":{"id":"https://genegraph.clinicalgenome.org/r/379a1f3e-19a7-460f-9205-68ccebd90ea7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_174889.5(NDUFAF2):c.1A>T (p.Met1Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA359935449"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a98c2797-eb0f-432c-ba3a-7a3219eef767_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The c.103delA mutation introduces a frameshift which leads to a truncated protein of 52 aa. SDS-PAGE western blot of NDUFAF2 and Porin (loading control) in control and patient fibroblasts shows complete absence of NDUFAF2 protein in DT67 indicating that any truncated NDUFAF2 protein products are unstable.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5cadf47-df21-4dd6-99bc-a7c4d0455291","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20818383","rdfs:label":"Calvo DT67","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"detectionMethod":"","phenotypeFreeText":"She died at 17 months of age and had a neuropathological diagnosis of Leigh syndrome. \n** Clinical information found in supplementary","phenotypes":["obo:HP_0001290","obo:HP_0001508","obo:HP_0000648","obo:HP_0000639"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a98c2797-eb0f-432c-ba3a-7a3219eef767_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20818383","allele":{"id":"https://genegraph.clinicalgenome.org/r/26b1bcd6-d651-4b78-a388-95f9cac7ec09","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_174889.5(NDUFAF2):c.103del (p.Ile35fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658655567"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/175103e9-6475-4495-bee4-1db5f8e6a673_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The mutation (c.114C>G; p.Tyr38X). introduces an early stopcodon resulting in a truncated protein. Additional 0.5 pts awarded for complementation assay studies. A baculovirus containing the GFP-tagged wild-type NDUFAF2 gene was used to prove the functional consequences of the mutation. The expression and activity of complex I was almost\ncompletely rescued by complementation of the patient fibroblasts with the baculovirus.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/196bc157-05a6-4516-915b-20b45682ec53","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19384974","rdfs:label":"Hoefs Index case","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":7,"detectionMethod":"Authors screened the NDUFS4 gene first since this gene is associated with a combined deficiency of complex I and III  and excluded any disease-causing mutations. Because of consanguinity we performed homozygosity mapping to identify regions on\nthe nuclear genome containing candidate genes and found 2 homozygous regions (>4 Mb). The size of the locus onchromosome 5 between the SNPs rs446155 and rs458362 was 4.5 Mb. This locus contained the assembly factor NDUFAF2. Amplification of the four exons of this gene and sequence analysis of genomic DNA of the patient demonstrated the presence of a homozygous substitution of C to G (c.114C>G; p.Tyr38X).","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"Laboratory investigations revealed elevated blood\nlactate concentrations ranging between 3-5 mmol/L (ref. <2.3 mmol/L). Elevated levels of fumarate and malate were present in the urine. Magnetic resonance imaging (MRI) of the brain and spinal cord showed symmetrical, bilateral, high signalling abnormalities in thalamus, cerebral peduncles, brainstem and spinal cord (Images are available for review). Authors noted clinical symptoms and MRI findings were consistent with Leigh syndrome (LS). Fibroblasts of the index patient displayed a marked decrease in complex I and a slight decrease in complex III to 21-23% and 82-98% of the lowest control value, respectively.","phenotypes":["obo:HP_0001263","obo:HP_0001947","obo:HP_0001290"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/175103e9-6475-4495-bee4-1db5f8e6a673_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19384974","allele":{"id":"https://genegraph.clinicalgenome.org/r/bab9c372-e7cd-4a89-b84f-a2ea10f9a0eb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_174889.5(NDUFAF2):c.114C>G (p.Tyr38Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3278074"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/043c053f-5379-4b35-8b82-37fdca49106a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Second unrelated proband with homozygous c.1A>T mutations (Score 0.5 pts)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ea2936bb-d42b-4907-9065-f104fb8bcb52","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18180188","rdfs:label":"Barghuti Patient 2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":8,"detectionMethod":"","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"At 18 months, he experience a sudden onset of repeated episodes of flaccidity and apnea.  He never regained consciousness and remained dependent on ventilatory support till his death, three months later.Brain MRI, performed at 19 months of age and one month after the acute event, disclosed involvement of the mamillothalamic tracts, substantia nigra/medial lemniscus, medial longitudinal fasciculus, spinothalamic tracts and periaqueductal gray matter. The cortex and subcortical white matter were relatively spared whereas the cerebellar hemispheres were only slightly affected. (Images available for review). Complex I activity in fibroblasts was 24% of control.","phenotypes":["obo:HP_0001270","obo:HP_0000648","obo:HP_0001290"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/043c053f-5379-4b35-8b82-37fdca49106a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18180188","allele":{"id":"https://genegraph.clinicalgenome.org/r/379a1f3e-19a7-460f-9205-68ccebd90ea7"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/eca4be36-318a-4c4f-bdc8-bc89c95a858b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The nonsense c.221G>A mutation predicts a truncated protein of 74 aa or, via exon skipping, causes a transcript encoding a frameshift and a truncated protein of 78 aa.  SDS-PAGE western blot of NDUFAF2 and Porin (loading control) in control and patient fibroblasts shows complete absence of NDUFAF2 protein indicating that any truncated NDUFAF2 protein products are unstable. (Awarded default 2 pts)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec491f31-1f32-40e4-b477-05ea31e727c6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20818383","rdfs:label":"Calvo DT16","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"detectionMethod":"","phenotypeFreeText":"Authors noted patient was diagnosed with Leigh syndrome based on his clinical course and MRI findings of mildly increased signal in the midbrain and deep white matter in the occipital regions (No images available for review).","phenotypes":["obo:HP_0001508","obo:HP_0002194","obo:HP_0001290","obo:HP_0000639"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/eca4be36-318a-4c4f-bdc8-bc89c95a858b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20818383","allele":{"id":"https://genegraph.clinicalgenome.org/r/cba40b97-63fd-4fe9-946f-bd7cf276fdd4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_174889.5(NDUFAF2):c.221G>A (p.Trp74Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3278149"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ebafef5f-8087-400c-a5ab-5159bfb0117e_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Case with homozygous nonsense mutations. Additional 0.5 pts awarded as authors showed that complex I defect could be rescued by retroviral expression of the B17.2L (yeast NDUFAF2 paralogue) in patient fibroblasts.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/46f49fae-d0ab-4e1c-9a8d-21d6f4449cf1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16200211","rdfs:label":"Ogilvie Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":12,"detectionMethod":"","phenotypeFreeText":"CSF lactate was slightly increased (4.2 mM; controls 1.4â€“3.9 mM). Brain MRI\nat age 3 showed symmetric lesions in the mamillothalamic tracts, substantia nigra/medial lemniscus, medial longitudinal fasciculus, and spinothalamic tracts. Confluent areas of hyperintense signal were also seen in the corpus medullare of the cerebellum. The amount and activity of complex I were less than 20% of control levels in immortalized patient fibroblasts as assessed by BN-PAGE and measurement of in-gel activity. Neuropathological examination of the cerebral hemispheres revealed striking spongiform changes throughout the white matter and deep gray matter with relative sparing of the cortex. (MRI images and additional neuropath language available for review)","phenotypes":["obo:HP_0002376","obo:HP_0001251"],"previousTesting":true,"previousTestingDescription":"Pyruvate dehydrogenase deficiency was excluded by activity measurement in peripheral blood lymphocytes","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ebafef5f-8087-400c-a5ab-5159bfb0117e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16200211","allele":{"id":"https://genegraph.clinicalgenome.org/r/526b15ae-1c1f-4b97-bd42-1778dd5434c2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_174889.5(NDUFAF2):c.139C>T (p.Arg47Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115096"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/7c26c06d-17dc-4783-8145-5de35c9a73f5_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7c26c06d-17dc-4783-8145-5de35c9a73f5_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8e807c71-d5ae-475b-a020-7d0a1703fd47","type":"EvidenceLine","dc:description":"Mouse cell line recapitulate a biochemical phenotype seen in Leigh or Leigh-like syndrome","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/574b9404-4226-4f2b-82aa-e33b2794bf3d","type":"Finding","dc:description":"Both human and the mouse cell line demonstrate complex I deficiency","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23702311","rdfs:label":"Ndufaf2 knock-out mice cell model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7c26c06d-17dc-4783-8145-5de35c9a73f5_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/521cc5e8-da8a-4f9d-afd8-18f930857e39","type":"EvidenceLine","dc:description":"The NDUFAF2 encoded protein shares a biochemical relationship or function with 6-10 gene products whose dysfunction is known to cause Leigh syndrome (Awarded 1.5 pt)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0a604543-5eec-4eac-bd73-e5bea2081c58","type":"Finding","dc:description":"NDUFAF2 is a nuclear encoded complex 1 assembly unit.  According to Leigh map, at least six other complex I assembly units have been implicated in causing Leigh Syndrome (NDUFAF6, NDUFAF4, NDUFAF5, FOXRED1, NUBPL, and C17ORF89) (Rahman 2017 PMID: 27977873). Therefore, the function of NDUFAF2 is shared with other known genes in the disease of interest.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16200211","rdfs:label":"NDUFAF2 complex I assembly unit","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9ca2764a-71c4-4891-88ff-2a15869f3873","type":"EvidenceLine","dc:description":"Evidence showing that protein expression is disrupted in any tissue or cell type and/or evidence expression in the brain. (Awarded 0.5 pts)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/763ffc62-bad6-4fc5-974d-58b7d6b6340e","type":"Finding","dc:description":"The Human Protein Atlas Atlas demonstrates that NDUFAF6 is expressed in all tissues on the RNA level (https://www.proteinatlas.org/ENSG00000156170-NDUFAF6/tissueProtein expression in the brain has been shown in the cerebral cortex, cerebellum, and basal ganglia. Points can be awarded as this expression profile is consistent with areas of pathology in Leigh-like syndrome","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25613900","rdfs:label":"NDUFAF2 Brain expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5}],"evidenceStrength":"Definitive","sequence":1509,"specifiedBy":"GeneValidityCriteria7","strengthScore":14.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/27cRY-MY_1k","type":"GeneValidityProposition","disease":"obo:MONDO_0009723","gene":"hgnc:28086","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7c26c06d-17dc-4783-8145-5de35c9a73f5-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}